相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
Enrico Costa et al.
ORPHANET JOURNAL OF RARE DISEASES (2022)
Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators
Karol Fiedorczuk et al.
SCIENCE (2022)
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial
Matthias Griese et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Rescue of multiple class II CFTR mutations by elexacaftor plus tezacaftor plus ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
Onofrio Laselva et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
Ciaran A. Shaughnessy et al.
SCIENTIFIC REPORTS (2021)
Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
Valeria Capurro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR
Guido Veit et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis
Chiara Brandas et al.
BIOMOLECULES (2021)
Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies
Fahad A. Almughem et al.
PHARMACEUTICS (2020)
From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis
Andrea Gramegna et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
Guido Veit et al.
JCI INSIGHT (2020)
Structural identification of a hotspot on CFTR for potentiation
Fangyu Liu et al.
SCIENCE (2019)
Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
Giulia Amico et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G. M. Heijerman et al.
LANCET (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Structure-guided combination therapy to potently improve the function of mutant CFTRs
Guido Veit et al.
NATURE MEDICINE (2018)
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Dominic Keating et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
J. C. Davies et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking
Carlos M. Farinha et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Cystic fibrosis: a clinical view
Carlo Castellani et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
New horizons for cystic fibrosis treatment
Isabelle Fajac et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Molecular Structure of the Human CFTR Ion Channel
Fangyu Liu et al.
CELL (2017)
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations
Gudio Veit et al.
MOLECULAR BIOLOGY OF THE CELL (2016)
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis
J. Stuart Elborn et al.
LANCET RESPIRATORY MEDICINE (2016)
Cystic fibrosis genetics: from molecular understanding to clinical application
Garry R. Cutting
NATURE REVIEWS GENETICS (2015)
The relative frequency of CFTR mutation classes in European patients with cystic fibrosis
K. De Boeck et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Corrector VX-809 stabilizes the first transmembrane domain of CFTR
Tip W. Loo et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Bithiazole Correctors Rescue CFTR Mutants by Two Different Mechanisms
Tip W. Loo et al.
BIOCHEMISTRY (2013)
Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain
Norbert Odolczyk et al.
EMBO MOLECULAR MEDICINE (2013)
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1
Hong Yu Ren et al.
MOLECULAR BIOLOGY OF THE CELL (2013)
Mechanism-based corrector combination restores ΔF508-CFTR folding and function
Tsukasa Okiyoneda et al.
NATURE CHEMICAL BIOLOGY (2013)
Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences
Juan L. Mendoza et al.
CELL (2012)
CFTR: folding, misfolding and correcting the ΔF508 conformational defect
Gergely L. Lukacs et al.
TRENDS IN MOLECULAR MEDICINE (2012)
Mechanisms of CFTR folding at the endoplasmic reticulum
Soo Jung Kim et al.
FRONTIERS IN PHARMACOLOGY (2012)
Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane
Tsukasa Okiyoneda et al.
SCIENCE (2010)
Mechanisms for Rescue of Correctable Folding Defects in CFTRΔF508
Diane E. Grove et al.
MOLECULAR BIOLOGY OF THE CELL (2009)
Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function
Adrian W. R. Serohijos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator
J. Michael Younger et al.
CELL (2006)
The short apical membrane half-life of rescued ΔF508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of ΔF508-CFTR in polarized human airway epithelial cells
A Swiatecka-Urban et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin
CA Farinha et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists
LVJ Galietta et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2001)
Green fluorescent protein-based halide indicators with improved chloride and iodide affinities
LJV Galietta et al.
FEBS LETTERS (2001)
Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator
WR Skach
KIDNEY INTERNATIONAL (2000)
分享论文
